Details of the Drug

General Information of Drug (ID: DMLXMCB)

Drug Name
COR-D
Indication
Disease Entry ICD 11 Status REF
T-cell leukaemia 2A90 Preclinical [1]
Drug Type
Small molecular drug
Cross-matching ID
TTD ID
DOJ6D9

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular signal-regulated kinase 1 (ERK1) TT1MG9E MK03_HUMAN Activator [2]
Extracellular signal-regulated kinase 2 (ERK2) TT4TQBX MK01_HUMAN Activator [2]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Activator [2]
Stress-activated protein kinase JNK2 (JNK2) TTHS0U8 MK09_HUMAN Activator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease T-cell leukaemia
ICD Disease Classification 2A90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Stress-activated protein kinase JNK1 (JNK1) DTT MAPK8 1.48E-07 1.2 2.27
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04022863) Ovarium Cancer Detection by TEP's and ctDNA. U.S. National Institutes of Health.
2 Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
3 DOI: 10.1158/1538-7445.AM2015-4693
4 Clinical pipeline report, company report or official report of HaiHe Biopharma.
5 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
6 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
7 ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
8 National Cancer Institute Drug Dictionary (drug name JSI1187).
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
12 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
13 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
14 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
15 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.